retatrutide triple agonist glp-1 gip glucagon phase 2 results Retatrutide: The Next Generation of Weight Loss Medication? Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon

The 25-34 audience stands out as the most receptive age group: over 54% would actively seek a prescription nearly 56% find pills more appealing than injections a striking 87.38% of current injectable users would consider switching to tablets This suggests oral GLP-1s may particularly resonate with younger working-age adults who value convenience, discretion, and familiarity with daily medication formats

Can prevent cancer, Parkinson's disease, and multiple sclerosis in the long run

Investigated for minimal impact on cortisol, prolactin, and aldosterone during GH release

Those on semaglutide 2.4 mg weekly had a 20% lower relative risk of major cardiovascular events, including heart attack and stroke, over a median follow-up of nearly 40 months

When administered, the peptide preferentially accumulates in adipose tissue, where it interacts with beta-3 adrenergic receptors on fat cell membranes and initiates metabolic signaling cascades